secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001819790-22-000045
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Pharma board chair Ackermann resigns; CEO Azamian succeeds; Yarno named lead independent director
--------------------------------------------------------------------------------

- Michael Ackermann resigned as Chairperson and Board member effective Dec 2, 2022; no disagreement with company.
- Ackermann entered a 12-month consulting agreement, receiving 5,000 RSUs vesting in one year and continued equity vesting.
- CEO Bobak Azamian appointed Board Chairperson effective Dec 2; will not receive additional compensation.
- Wendy Yarno appointed Lead Independent Director effective Dec 2; granted 5,000 RSUs vesting in one year and $75,000 annual cash retainer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000045/0001819790-22-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000045/tars-20221201.htm
  HTML page:      https://secwatch.observer/filing/0001819790-22-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer